Gilead Sciences Inc. started two late-stage studies to test the company’s drug in patients with severe and moderate cases of the illness caused by the coronavirus, sending the drug firm’s shares up.

The World Health Organization (WHO) said it was too early to say China’s coronavirus outbreak was peaking, but noted that one day earlier was the first that the overall number of new cases in China had dropped.